Biomark Diagnostics (STU:20B) Interest Expense: €-0.04 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:20B Biomark Diagnostics Inc STU:20B
27 GF Score
Price €0.32
! 4 Warning Signs
View Full Analysis

What is Biomark Diagnostics Interest Expense?

Biomark Diagnostics STU:20B 27 Interest Expense is €-0.04 Mil as of Mar. 2026. GuruFocus rates STU:20B with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biomark Diagnostics's interest expense for the three months ended in Mar. 2026 was € -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biomark Diagnostics's Operating Income for the three months ended in Mar. 2026 was € -0.16 Mil. Biomark Diagnostics's Interest Expense for the three months ended in Mar. 2026 was € -0.02 Mil. Biomark Diagnostics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biomark Diagnostics  (STU:20B) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biomark Diagnostics's Interest Expense for the three months ended in Mar. 2026 was €-0.02 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-0.16 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.27 Mil.

Biomark Diagnostics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Biomark Diagnostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Biomark Diagnostics Interest Expense Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics Interest Expense Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.08 -0.08 -0.04 -0.04

Biomark Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.00 -0.01 -0.02
STU:20B
27GF Score
Biomark Diagnostics Inc STU:20B
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.04 Mil mean?
Biomark Diagnostics (STU:20B) has a Interest Expense of €-0.04 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biomark Diagnostics and its competitors.
Is Biomark Diagnostics' Interest Expense too high?
Biomark Diagnostics' current Interest Expense is €-0.04 Mil. Overall, Biomark Diagnostics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' Interest Expense compare to TMO and DHR?
Biomark Diagnostics' Interest Expense of €-0.04 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Diagnostics & Research company?
A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current Interest Expense is €-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (STU:20B) has a current Interest Expense of €-0.04 Mil. The current Interest Expense is €-0.04 Mil. Biomark Diagnostics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Biomark Diagnostics (STU:20B), the current Interest Expense is €-0.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Other Exchanges BMKDF:USABUX:Canada
Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
27GF Score

Get the complete analysis for STU:20B

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price